Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cti Biopharm Corp 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 USA

www.ctibiopharma.com P: 206-282-7100 F: 206-284-6206

Description:

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 1,198,789
Enterprise Value, $K 1,227,919
Shares Outstanding, K 131,880
Annual Sales, $ 53,950 K
Annual Net Income, $ -92,990 K
Last Quarter Sales, $ 24,120 K
Last Quarter Net Income, $ -13,420 K
60-Month Beta 0.83
% of Insider Shareholders 7.61%
% of Institutional Shareholders 91.45%
Float, K 121,844
% Float 92.39%
Short Volume Ratio 0.15

Growth:

1-Year Return 52.52%
3-Year Return 621.43%
5-Year Return 82.53%
5-Year Revenue Growth 114.51%
5-Year Earnings Growth 34.68%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 05/15/23
Next Earnings Date 08/14/23
Earnings Per Share ttm -0.58
EPS Growth vs. Prev Qtr 28.57%
EPS Growth vs. Prev Year 72.97%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 01/03/17

CTIC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -55.82%
Profit Margin % -172.36%
Debt/Equity -2.70
Price/Sales 22.62
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.19
Interest Coverage -6.08
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar